Piper Sandler analyst David Westenberg maintained a Buy rating on Akoya Biosciences (AKYA – Research Report) today and set a price target of $8.00. The company’s shares closed yesterday at $4.12.
Westenberg covers the Healthcare sector, focusing on stocks such as Natera, Exact Sciences, and Myriad Genetics. According to TipRanks, Westenberg has an average return of -0.1% and a 41.46% success rate on recommended stocks.
Akoya Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $8.10, representing a 96.60% upside. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $6.00 price target.
AKYA market cap is currently $203.4M and has a P/E ratio of -2.77.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akoya Biosciences (AKYA) Company Description:
Akoya Biosciences Inc is an an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. It offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.
Read More on AKYA:
- AKYA Earnings this Week: How Will it Perform?
- Akoya, NeraCare enter exclusive agreement for personalized therapy selection
- Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
- Akoya Biosciences opens Operations and Manufacturing Center in Marlborough
- Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
